Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Joseph Payne

Pad (Padmanabh) Chivukula

Arcturus Therapeutics Holdings Inc.

Texas Biomedical Research Institute focuses on basic and translational research to advance human health and eradicate infectious diseases. It has a history of developing significant therapies and vaccines.

Texas Biomedical Research Institute

Arcturus Therapeutics is a global late stage-clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases

Biomedical Advanced Research and Development Authority (BARDA)

Arcturus Therapeutics

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update 
and Pipeline Progress.

https://lnkd.in/eAgf78gv

#nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTCD #CF #ClinicalTrial #RareDiseases #Innovation #FinancialResults #Arcturus #ARCT $ARCT


We are delighted to announce that Arcturus Therapeutics was named on Deloitte's list of North America's most innovative, fastest-growing companies.
https://lnkd.in/ev8PTq8

#Fast500 #nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTC #CF #RareDiseases #Innovation #ARCT #Arcturus $ARCT

Dr. Igor Smolenov, Arcturus Therapeutics' Chief Development Officer is presenting at the 11ᵗʰ International mRNA Health Conference on Wednesday, November 1, 2023.
#Coronavirus #Vaccine #mRNA #RareDisease #ClinicalTrial #NextGenmRNA #mRNAhealthconference #mRNAconference #saRNA #mRNA2023 #Innovation #Arcturus $ARCT

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023. 
#nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTC #CF #ClinicalTrial #RareDiseases #Innovation #FinancialResults #ARCT $ARCT



Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences. $ARCT

Metric
Company Name	Arcturus Therapeutics Holdings Inc.	Texas Biomedical Research Institute
Symbol	ARCT
MSH ID	COM:ARCTURUSRX	ORG:TXBIOMED
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Research and Development
Country	US	US
Stage
Employee Count	180
Website	arcturusrx.com	txbiomed.org
LinkedIn	arcturus-therapeutics
Founders

Metric
Market Cap	585.23M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	157.75M
Revenue (LTM)
Revenue (NTM)
Gross Profit	154.79M
EBITDA	-1.20M
Operating Income	-4.15M
Net Income	-29.73M
EPS	-1.12
Diluted EPS	-1.12
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1.02
Operating Profit Margin	-0.42
EBITDA Margin	-0.01
Net Profit Margin	-0.17
Return on Equity	-0.09
Return on Assets	-0.06
Return on Capital Employed	-0.20

COM:ARCTURUSRX

Arcturus Therapeutics

Last Close

17.07

22/11 21:00

Market Cap

585.23M

Beta: -

Volume Today

512.97K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	9.33
P/B Ratio	3.31
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	10.51
EV Multiple	-7.40

Metric
Days Sales Outstanding	47.66
Days Payables Outstanding	64.17
Days Inventory Outstanding	410.79
Operating Cycle	497.61
Cash Conversion Cycle	1.81K
Asset Turnover	0.40

Metric
Operating Cash Flow	-18.10M
Free Cash Flow	-21M
Cash Flow to Debt	0.44
Operating Cash Flow/Sales	0.11
Free Cash Flow Yield	0.15

Metric
Cash & Equivalents	347.00M
Accounts Receivable	-29.30M
Inventory
Goodwill
Debt to Capitalization	0.11
Debt to Assets	0.11
Current Ratio	4.49
Quick Ratio	4.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11
R&D to Revenue	0.62
SG&A to Revenue	0.18